David R. Epstein - Apr 21, 2022 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role: Director
Signature: /s/ Joanne M. Protano, Attorney-in-Fact
Stock symbol: RUBY
Transactions as of: Apr 21, 2022
Transactions value $: $43,329
Form type: 4
Date filed: 4/22/2022, 06:07 PM
Previous filing: Apr 1, 2022
Next filing: May 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RUBY	Common Stock	Purchase	$43.3K	+30K	+0.64%	$1.44^*	4.72M	Apr 21, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.50, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.50, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.